Company / R&D Expense
Trevi Therapeutics, Inc. R&D Expense History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$39.4M
FY2024
5-year range
$19.8M / $39.4M
FY2020-FY2024
Trend
+66.3%
vs FY2023
Sector context
#185 of 210
Health Care
What the data says
Trevi Therapeutics, Inc.'s r&d expense of $39M is lower than 88% of companies in the Health Care sector (FY2024). Improved from $20M to $39M over the past 2 years.
Based on SEC 10-K filings.
$39M in FY2024 with a 5-year CAGR of +15.3%.
Improved from $20M to $39M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +19.7%
- 5-Year CAGR
- +15.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 210This company $39.4M Sector average $644.1M
▼
-93.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.3%, indicating consistent growth.
- In FY2024, r&d expense increased 66.3% year-over-year.
- Ranks #185 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $39.4M | +66.3% |
| FY2023 | $23.7M | +19.4% |
| FY2022 | $19.8M | -13.7% |
| FY2021 | $23.0M | +2.9% |
| FY2020 | $22.3M | +15.5% |
| FY2019 | $19.3M | +37.4% |
| FY2018 | $14.1M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026